Back to search

National and Kapodistrian University of Athens

Γονοτυπικός έλεγχος ACE, APO-E, angiotensinogen, β3-adrenergic receptor σε ασθενείς με στεφανιαία νόσο

Abstract

dc:description

Coronary artery disease (CAD) is the most common disease of the cardiovascular system. Atherosclerosis is the main cause of the disease and it is considered as a chronic inflammatory response of the vessel wall with autoimmunity characteristics. The disease featuring considerable heterogeneity as to the cause and nature of the lesions and research directed to decipher the complexity of the atherosclerotic process. So, a complex genetic factors in interaction with environmental factors, it seems that identify and define the genetic susceptibility to the disease, as well as the progress, evolution, and the severity. Genetic control of patients with coronary artery disease is to identify persons predisposed to the occurrence of CAD, with the possibility of prevention and / or the appropriate therapeutic intervention.This study determined genetic polymorphisms of the renin-angiotensin-aldosterone system (RAAS): ACE, AGT, b3-AR, genetic polymorphisms of APO-E, as well as genetic polymorphisms of MHC and more specifically the HLA-A,-B,-Cw,-DR,-DQ loci. Our findings have as follows:Polymorphisms of ACE: No statistically significant differences were observed in patients with CAD compared to the controls. Particular interest is the finding that the genotype II, which according to the available literature is considered protective factor coronary artery disease in manifestation, occurred with equal frequency in patients and controls. Polymorphisms of APO-E: From literature alleles E2, E3, E4 are independent risk factors for the onset of myocardial infarction. In our study we observed that the genotypesE2E4 and E3E3 are statistically significantly correlated with coronary artery disease . Interestingly, the correlation of coronary artery disease with genotype E3E3 observed not mentioned in the literature accessible. Genotypes E2E3 and E3E4 were also observed with increased frequency but these differences are not controlled statistically significant.Polymorphisms of b3-AR: There were no statistically significant differences in the group of patients with CAD compared to the controls. Specifically, the AA genotype, in which a limited number of studies have associated with CAD, was found only in one patient and in no control.Polymorphisms AGT: There emerged positive or negative correlations of genotypes of AGT with coronary artery disease. The TT genotype which was associated with the disease in young patients and to the size of fat cells, was detected in only two patients and in one control.Polymorphisms of HLA antigens: There was a significant increase in the frequency of HLA-A23, Cw3, DR4, DR16, DQ6, DQ8 antigens and significant decrease in the frequency of HLA-A3, Cw12, DR11 antigens in patients with coronary artery disease. To these HLA antigens the value of p was corrected for multiple testing (Bonferroni correction for multiple testing) and finally for HLA Cw3, DR11, DR16 antigens their correlation with coronary artery disease remained statistically significant. So it could be proposed that the HLA-Cw3 and HLA-DR16 predispose to CAD while HLA-DR11 offers protection from the CAD.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Athanasiadis, Theofilos
  • Αθανασιάδης, Θεόφιλος

Subjects

dc:subject × 15

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38701

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Athanasiadis, Theofilos; Αθανασιάδης, Θεόφιλος. Γονοτυπικός έλεγχος ACE, APO-E, angiotensinogen, β3-adrenergic receptor σε ασθενείς με στεφανιαία νόσο. National and Kapodistrian University of Athens, 2013. http://hdl.handle.net/10442/hedi/38701